All In Biotech

Drug Trial Radar · NCT07227597

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Nov 29, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

  • GocatamigDrug

    Intravenous (IV) administration

  • I-DXdDrug

    IV administration

  • AtezolizumabDrug

    IV administration

  • CarboplatinDrug

    IV administration

  • EtoposideDrug

    IV administration

  • Rescue MedicationsDrug

    Participants will receive rescue medications at the investigator's discretion. Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related reaction (IRR) prophylaxis; and 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, neurokinin 1 (NK-1) receptor antagonist, and corticosteroid for prevention of nausea and vomiting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 58 months
  2. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 21 days
  3. Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 58 months
  4. Objective Response Rate (ORR)Time frame: Up to approximately 58 months

Locations

58 sites in 13 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation ( Site 0124)

    Santa Rosa, California · Recruiting

  • University of Colorado, Anschutz Cancer Pavilion ( Site 0125)

    Aurora, Colorado · Recruiting

  • Orlando Health Cancer Institute ( Site 0108)

    Orlando, Florida · Recruiting

  • Saint Elizabeth Medical Center Edgewood ( Site 0112)

    Edgewood, Kentucky · Recruiting

  • Washington University School of Medicine ( Site 0134)

    St Louis, Missouri · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101)

    Hackensack, New Jersey · Recruiting

  • Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107)

    Portland, Oregon · Recruiting

  • Avera Cancer Institute- Research ( Site 0104)

    Sioux Falls, South Dakota · Recruiting

  • The University of Tennessee Medical Center ( Site 0120)

    Knoxville, Tennessee · Recruiting

  • Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133)

    Memphis, Tennessee · Recruiting

  • SCRI Oncology Partners ( Site 7000)

    Nashville, Tennessee · Recruiting

  • Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113)

    Houston, Texas · Recruiting

  • University of Virginia Health System ( Site 0122)

    Charlottesville, Virginia · Recruiting

  • CEMIC ( Site 1903)

    Caba., Buenos Aires, Argentina · Recruiting

  • Hospital Austral ( Site 1901)

    Pilar, Buenos Aires, Argentina · Recruiting

  • Sanatorio Parque ( Site 1900)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Fundación Arturo López Pérez ( Site 0200)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 0202)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0201)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer Hospital ( Site 1604)

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Provincial Cancer Hospital ( Site 1607)

    Fuzhou, Fujian, China · Recruiting

  • Southern Medical University Nanfang Hospital ( Site 1608)

    Guangzhou, Guangdong, China · Recruiting

  • Jiangmen Central Hospital ( Site 1611)

    Jiangmen, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital ( Site 1606)

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Nanchang University ( Site 1610)

    Nanchang, Jiangxi, China · Recruiting

  • Shanghai East Hospital ( Site 1600)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Cancer hospital. ( Site 1609)

    Chengdu, Sichuan, China · Recruiting

  • The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 1602)

    Hangzhou, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province ( Site 1601)

    Taizhou, Zhejiang, China · Recruiting

  • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne ( Site 0401)

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Jena ( Site 0403)

    Jena, Thuringia, Germany · Recruiting

  • European Interbalkan Medical Center ( Site 0500)

    Thessaloniki, Greece · Recruiting

  • European Interbalkan Medical Center ( Site 0505)

    Thessaloniki, Greece · Recruiting

  • Errikos Dunant Hospital Center ( Site 0501)

    Athens, Attica, Greece · Recruiting

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0502)

    Athens, Attica, Greece · Recruiting

  • Athens Medical Center ( Site 0504)

    Athens, Attica, Greece · Recruiting

  • University General Hospital of Heraklion ( Site 0503)

    Heraklion, Irakleio, Greece · Recruiting

  • Rambam Health Care Campus ( Site 0602)

    Haifa, Israel · Recruiting

  • Sheba Medical Center ( Site 0601)

    Ramat Gan, Israel · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0701)

    Milan, Italy · Recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.